Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Five Prime Therapeutics

This page shows the latest Five Prime Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Amgen plans acquisition of Rodeo Therapeutics

Amgen plans acquisition of Rodeo Therapeutics

In March, Amgen struck another, costlier deal to acquire Five Prime Therapeutics for $1.9bn, in a bid to bolster its oncology pipeline. ... Following the acquisition, Amgen will gain Five Prime’s pipeline of immuno-oncology assets – including the

Latest news

  • Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition

    Five Prime's pipeline includes potentially first-in-class anti-FGFR2b antibody bemarituzumab. Amgen has announced an agreement to acquire Five Prime Therapeutics for approximately $1.9bn, gaining a phase 2 ... pre-existing co-development and

  • BMS’ Opdivo combo misses the mark in pancreatic cancer BMS’ Opdivo combo misses the mark in pancreatic cancer

    Failed to reach primary endpoint of progression-free survial. A combination of Bristol-Myers Squibb’s Opdivo and Five Prime Therapeutics’ cabiralizumab failed to demonstrate efficacy in advanced pancreatic cancer. ... in this randomised, controlled

  • BMS signs $1.74bn deal to boost immuno-oncology portfolio BMS signs $1.74bn deal to boost immuno-oncology portfolio

    Gainsaccess to Five Prime Therapeutics CSF1R antibody programme. Bristol-Myers Squibb has paid £350m upfront to Five Prime Therapeutics to gain rights to a development programme that complements its cancer immunotherapy ... BMS and Five Prime have been

  • BMS strikes $350m deal to boost its immuno-oncology pipeline BMS strikes $350m deal to boost its immuno-oncology pipeline

    Will collaborate with US biotech Five Prime Therapeutics. Bristol-Myers Squibb has signed a $350m deal to boost its immuno-oncology pipeline, following through on its promise last year to increase ... The pharma company will collaborate with San Francisco

  • GSK forms two new drug partnerships

    GSK has entered partnerships with both biotech Amplimmune to develop cancer therapies, and Five Prime Therapeutics for skeletal muscle disorders. ... GSK's deal with San Francisco-based Five Prime Therapeutics, which is worth around $139m before

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    cash and $30m equity) to gain access to CRISPR Therapeutics' technology for gene editing. ... Acquisition - company. 2, 300. Five Prime Therapeutics/ Bristol-Myers Squibb. CSF1R antibody programme, incl FPA008 (p1) in immunology/ oncology in combination

  • Pharma deals in May 2015 Pharma deals in May 2015

    Interestingly though, it is not always the major players as evidenced by the deals between bluebird bio with Five Prime Therapeutics and Editas with Juno Therapeutics. ... Five Prime/ bluebird bio. Licence agreement. For development of CAR-T cell

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Company divestment. 1, 530. Proteostasis Therapeutics / Astellas. Therapeutics modulating Unfolded Protein Response - multiple programmes. ... Cerdelga (eliglustat) sold by Vertex. Acquisition 75% royalty stream. 66. Five Prime Therapeutics / BMS.

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    Vidara Therapeutics/. Horizon Pharma. Merger/ acquisition. Actimmune (interferon gamma-1b) for CGD and SMO (approved). ... 660. Five Prime Therapeutics/ BMS. Collaboration, licence. Drug discovery against two undisclosed targets in immune checkpoint

  • Pharma deals during March 2014 Pharma deals during March 2014

    The first of these deals was between recently floated Five Prime Therapeutics and Bristol-Myers Squibb (BMS) under which the companies will collaborate to discover, develop and commercialise immuno-oncology therapies. ... BMS is paying $20m upfront and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....

Quick links